VRTX in the 13F filings
Vertex Pharmaceuticals Inc · CUSIP 92532F100
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 35
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 20 listed it in both
- Shares listed
- 70,400,273
- combined, among listed positions
- Reported value
- $31.9bn
- combined, at the quarter end
Among the 92 comparable managers: 19 buyers (opened or added shares) and 20 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +3,451,758.
Managers listing VRTX in Q4 2025
35 of 35 holders
Largest increases and reductions, by shares
Increases
- Invesco Ltdexisting position · 7,852,733 shares now+5,755,936
- Capital Research Global Investorsexisting position · 17,316,344 shares now+763,063
- Millennium Management LLCexisting position · 365,664 shares now+324,622
- Citadel Advisors LLCexisting position · 427,060 shares now+253,558
- Arrowstreet Capital LPexisting position · 593,947 shares now+212,752
Reductions
- Fidelity (FMR LLC)existing position · 2,212,596 shares now-1,091,172
- Wellington Management Group LLPexisting position · 3,821,731 shares now-950,311
- T. Rowe Price Associates Incexisting position · 2,278,958 shares now-764,847
- Capital World Investorsexisting position · 25,510,182 shares now-400,405
- MFS Investment Managementexisting position · 211,934 shares now-291,226
New positions and exits
New (4)
Exited (4)
- Freestone Grove Partners LPwas $43m
- Voloridge Investment Management LLCwas $41m
- D. E. Shaw & Co.was $1.3m
- GAMCO Investors Incwas $201k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 13 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 12 | $4.6bn | n.a. | n.a. |
| Q4 2013 | 9 | $4.8bn | n.a. | n.a. |
| Q1 2014 | 11 | $4.9bn | n.a. | n.a. |
| Q2 2014 | 11 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 14 | $9.0bn | n.a. | n.a. |
| Q4 2014 | 15 | $9.3bn | n.a. | n.a. |
| Q1 2015 | 21 | $9.2bn | n.a. | n.a. |
| Q2 2015 | 23 | $9.4bn | n.a. | n.a. |
| Q3 2015 | 22 | $8.3bn | n.a. | n.a. |
| Q4 2015 | 19 | $10.2bn | n.a. | n.a. |
| Q1 2016 | 18 | $6.8bn | n.a. | n.a. |
| Q2 2016 | 13 | $7.5bn | n.a. | n.a. |
| Q3 2016 | 14 | $7.7bn | n.a. | n.a. |
| Q4 2016 | 14 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 21 | $9.5bn | n.a. | n.a. |
| Q2 2017 | 24 | $11.0bn | n.a. | n.a. |
| Q3 2017 | 28 | $12.6bn | n.a. | n.a. |
| Q4 2017 | 24 | $12.2bn | n.a. | n.a. |
| Q1 2018 | 24 | $13.3bn | n.a. | n.a. |
| Q2 2018 | 27 | $14.0bn | n.a. | n.a. |
| Q3 2018 | 26 | $15.7bn | n.a. | n.a. |
| Q4 2018 | 27 | $14.6bn | n.a. | n.a. |
| Q1 2019 | 26 | $17.0bn | n.a. | n.a. |
| Q2 2019 | 24 | $17.0bn | n.a. | n.a. |
| Q3 2019 | 25 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 29 | $20.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $20.9bn | n.a. | n.a. |
| Q2 2020 | 27 | $23.4bn | n.a. | n.a. |
| Q3 2020 | 31 | $21.9bn | n.a. | n.a. |
| Q4 2020 | 30 | $18.4bn | n.a. | n.a. |
| Q1 2021 | 31 | $15.4bn | n.a. | n.a. |
| Q2 2021 | 30 | $12.7bn | n.a. | n.a. |
| Q3 2021 | 35 | $10.1bn | n.a. | n.a. |
| Q4 2021 | 28 | $12.4bn | n.a. | n.a. |
| Q1 2022 | 23 | $16.1bn | n.a. | n.a. |
| Q2 2022 | 25 | $18.1bn | n.a. | n.a. |
| Q3 2022 | 22 | $18.4bn | n.a. | n.a. |
| Q4 2022 | 28 | $18.4bn | n.a. | n.a. |
| Q1 2023 | 26 | $21.4bn | n.a. | n.a. |
| Q2 2023 | 27 | $24.7bn | n.a. | n.a. |
| Q3 2023 | 33 | $24.3bn | n.a. | n.a. |
| Q4 2023 | 32 | $28.6bn | 16 | 16 |
| Q1 2024 | 31 | $29.8bn | 16 | 19 |
| Q2 2024 | 29 | $33.4bn | 12 | 18 |
| Q3 2024 | 27 | $33.5bn | 17 | 10 |
| Q4 2024 | 26 | $28.5bn | 14 | 13 |
| Q1 2025 | 21 | $35.4bn | 10 | 11 |
| Q2 2025 | 21 | $32.3bn | 11 | 11 |
| Q3 2025 | 22 | $25.9bn | 13 | 10 |
| Q4 2025 | 26 | $31.8bn | 19 | 20 |
| Q1 2026 | 25 | $31.8bn | 17 | 21 |
| Q2 2026 | 26 | $34.6bn | 21 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VRTX and LLY →VRTX and JNJ →VRTX and GILD →Choose a stock to compare with VRTX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VRTX, latest filings →Back to the 13F Explorer →